Evidence map›Paper›PMID 41221266›Full record

ArticleFrontiers in aging neuroscience2025

Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson's disease: a 12-year longitudinal study.

Kyoungwon Baik, Minwoong Kang, Yu Jeong Park, Su Jin Chung, Kyungmi Oh, Sung Hoon Kang, Seong-Beom Koh

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kyoungwon Baik *Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Minwoong Kang *Department of Biomedical Research Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Yu Jeong ParkDepartment of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Su Jin ChungDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
Kyungmi OhDepartment of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Sung Hoon Kang *Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Seong-Beom Koh *Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Various comorbidities contribute to mortality in patients with Parkinson's disease (PD). Although growing evidence demonstrates that chronic kidney disease (CKD) increases the risk of developing PD, the effect of CKD on all-cause mortality remains unclear. Methods: We enrolled 59,293 patients aged ≥40 years with Results: Parkinson's disease patients with CKD (hazard ratio [HR] = 1.240, 95% confidence interval [CI] 1.190-1.283) and proteinuria (HR = 1.543, 95% CI 1.457-1.634) had a higher risk of mortality, even after controlling for confounding factors. The degree of kidney dysfunction ( Conclusion: Chronic kidney disease and proteinuria were associated with a higher all-cause mortality in patients with PD in a dose-dependent manner. Furthermore, these results highlight that strategies for controlling kidney function are necessary to reduce mortality in patients with PD.

Indexed as

chronic kidney diseasekidney functionmortalityParkinson’s diseaseproteinuria

Identifiers

PMID41221266
PMCPMC12597998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.